Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Foghorn Therapeutics (FHTX) Current Deferred Revenue: 2020-2025

Historic Current Deferred Revenue for Foghorn Therapeutics (FHTX) over the last 5 years, with Sep 2025 value amounting to $65.3 million.

  • Foghorn Therapeutics' Current Deferred Revenue rose 95.60% to $65.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $65.3 million, marking a year-over-year increase of 95.60%. This contributed to the annual value of $45.6 million for FY2024, which is 32.00% up from last year.
  • Per Foghorn Therapeutics' latest filing, its Current Deferred Revenue stood at $65.3 million for Q3 2025, which was up 9.33% from $59.7 million recorded in Q2 2025.
  • In the past 5 years, Foghorn Therapeutics' Current Deferred Revenue registered a high of $65.3 million during Q3 2025, and its lowest value of $15.0 million during Q1 2021.
  • Over the past 3 years, Foghorn Therapeutics' median Current Deferred Revenue value was $33.9 million (recorded in 2023), while the average stood at $40.8 million.
  • As far as peak fluctuations go, Foghorn Therapeutics' Current Deferred Revenue spiked by 1,299.06% in 2021, and later fell by 14.52% in 2023.
  • Over the past 5 years, Foghorn Therapeutics' Current Deferred Revenue (Quarterly) stood at $28.3 million in 2021, then increased by 15.90% to $32.8 million in 2022, then increased by 5.27% to $34.5 million in 2023, then soared by 32.00% to $45.6 million in 2024, then skyrocketed by 95.60% to $65.3 million in 2025.
  • Its Current Deferred Revenue stands at $65.3 million for Q3 2025, versus $59.7 million for Q2 2025 and $51.7 million for Q1 2025.